Translational Oncology Solutions

Sep 20 2011 2:30 PM

Champions Oncology’s TumorGraft™ Platform and Translational Oncology Solutions is an innovative platform technology able to accelerate the development of oncology drugs by predicting their clinical effectiveness. This platform is based on primary tumor models of cancer that preserve the original characteristics of the human tumor. As a result, Champions TumorGraft™ (CTG) technology is more predictive than traditional xenograft models and correlates 100% to actual patient outcomes.

Champions TumorGrafts™ and Translational Oncology Solutions provide:

  • Early identification of  agent efficacy, ideal tumor type and potential combination therapies
  • A focused, accelerated and higher probability translational path into clinical trials and market launch
  • Biomarker discovery and potential companion diagnostics

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.